054
Test #
IgA & IgG Gliadin (Peptides) Antibody
CPT Code(s) #
86258 x2
If Profile, Includes Tests:
N/A
Disease Name:
GSE, Celiac Disease, Dermatitis Herpetiformis
Type of Study:
Serum Studies
Methodology:
ELISA
Substrate:
ELISA plate
Reference Range:
Gliadin IgA/IgG (Units)
• Negative <20
• Weak Positive 20-30
• Moderate to Strong Positive >30
Units:
Units
Schedule:
Assay performed once every week.
Specimen Requirements:
Collect 2-5 ml of blood in a red top Vacutainer or serum separator (SST) tube, allow blood to clot, and centrifuge. Label tube appropriately.
Sample Stability:
Room temperature = stable during shipment
2ºC to 8ºC = 5 days
-25ºC to -15ºC = 1 year
Clinical Relevance:
The diagnosis of celiac disease (CD) is based on mucosal changes detected by duodenal biopsy and positive serological tests (anti-tTG antibodies, anti-endomysium antibodies (EmA), and deamidated gliadin peptide (DGP) antibodies). Test for anti-deamidated peptides of gliadin (DGP) have replaced classic anti-native gliadin (AGA) tests. DGP IgG assays have a considerably higher diagnostic accuracy than AGA assays, and can replace anti-tTG tests in patients with selective IgA deficiency. The combination of IgG anti-DGP plus IgA anti-tTG assays show greater sensitivity than a single test, with very high specificity. IgG DGP are particularly useful in identifying CD in early childhood (age < 2 years). The reported sensitivity and specificity of Anti-Gliadin DP antibodies in celiac disease is 84.4% and 98.5%. The PPV and NPV have been reported as 98.2% and 86.8% respectively. However, the definitive diagnosis of CD should be based on clinical, molecular, and histopathological findings.
